The growing complexity of central nervous system (CNS) indications – from Alzheimer’s to schizophrenia to epilepsy – highlights the need for safer, more cost-effective treatment options. Biopharmaceutical companies developing CNS therapies face a number of challenges, including poor medication compliance, the need for intensive care delivery and multiple caregivers, the heterogeneous trial population and a tough regulatory environment. To help you provide the evidence your stakeholders demand, Quintiles offers deep expertise and experience in real-world and late phase CNS research. We can effectively transition evidence development efforts from early phase research into Phase IIIB and post-approval studies, delivering high-quality data to help improve your products’ chance of success in the marketplace.